Advances in the pharmacotherapeutic management of dementia with Lewy bodies

Expert Opinion on Pharmacotherapy
Giovanni PalermoUbaldo Bonuccelli

Abstract

Dementia with Lewy bodies (DLB) is the second most common type of dementia in people over 65 years of age. Given the complex clinical phenotype, the management of DLB may be challenging, especially considering that there is limited evidence about specific interventions, and there are currently no Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved medications. This article provides an overview of the current pharmacotherapy in DLB and gives review to the most recent drug candidates in clinical trials. Commonly prescribed drugs are primarily aimed at treating the most troublesome clinical features of DLB. Although these medications provide some benefit to symptoms, there is, unfortunately, a lack of DLB-specific evidence on effective treatments and their off-label use. Indeed, most treatments used come from clinical trials on patients with Alzheimer's disease or Parkinson's disease. Thus, there is an urgent need for randomized clinical trials in DLB patients. Despite several challenges, potential new drugs are in ongoing clinical trials; furthermore, as our understanding of molecular and cellular mechanisms underlying DLB broaden, it is likely that we will identify novel drug targets for the development o...Continue Reading

References

Nov 1, 1995·Epilepsy Research·M OkadaY Fukushima
Feb 15, 2002·Brain : a Journal of Neurology·A J HardingG M Halliday
Feb 15, 2002·Dementia and Geriatric Cognitive Disorders·Jeffrey L CummingsW Scott Clark
Oct 9, 2002·Archives of General Psychiatry·Pietro TiraboschiJody Corey-Bloom
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
Jul 31, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·David J BurnIan G McKeith
May 26, 2004·Neurology·P ThaisetthawatkulP A Low
Aug 18, 2004·Journal of Geriatric Psychiatry and Neurology·Dag AarslandIan G McKeith
Apr 9, 2005·Journal of the American Geriatrics Society·Makoto Tanaka, Toru Kita
Aug 19, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·S MolloyD J Burn
Jan 13, 2006·Brain : a Journal of Neurology·Pietro TiraboschiJody Corey-Bloom
Mar 1, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Lon S SchneiderPhilip S Insel
Apr 15, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·D J BurnI G McKeith
Apr 26, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Guido AlvesDag Aarsland
Jan 4, 2007·Neurology·Miho MurataUNKNOWN Japan Zonisamide on PD Study Group
Mar 14, 2007·Neurology·C F LippaUNKNOWN DLB/PDD Working Group
Apr 6, 2007·Dementia and Geriatric Cognitive Disorders·Keith EdwardsStewart Johnson
Apr 7, 2007·Brain : a Journal of Neurology·B F BoeveH Braak
Apr 25, 2007·Neurology·Roger KurlanUNKNOWN Alzheimer's Disease Cooperative Study Group
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael J Minzenberg, Cameron S Carter
Aug 12, 2008·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Tammy T HshiehSharon K Inouye
Oct 1, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Jennifer G GoldmanGlenn T Stebbins
Sep 8, 2009·Journal of the Neurological Sciences·Dag Aarsland, Martin Wilhelm Kurz
Nov 13, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Herbert Y MeltzerJoseph H Friedman
Apr 14, 2010·Archives of Neurology·Benedicte BallangerSusan H Fox
Jul 10, 2010·Parkinsonism & Related Disorders·Claudio LucettiUbaldo Bonuccelli
Jul 14, 2010·Alzheimer Disease and Associated Disorders·Sandi CuloBruce G Pollock
Sep 28, 2010·International Journal of Geriatric Psychiatry·Victoria LarssonElisabet Londos
Nov 30, 2011·Dementia and Geriatric Cognitive Disorders·Victoria LarssonElisabet Londos
Jul 26, 2012·Annals of Neurology·Etsuro MoriUNKNOWN Donepezil-DLB Study Investigators
Aug 16, 2012·American Journal of Alzheimer's Disease and Other Dementias·Eduardo PradoJohn M Ringman
Nov 1, 2012·Acta Neurologica Scandinavica. Supplementum·M J BrodieL Giorgi
Feb 13, 2013·Journal of Neurology·Marco OnofrjBernardo Perfetti

❮ Previous
Next ❯

Citations

Jan 15, 2020·Expert Opinion on Pharmacotherapy·Kurt A Jellinger
Jan 27, 2019·Drugs & Aging·Linda A Hershey, Rhonda Coleman-Jackson
Oct 16, 2019·Expert Opinion on Investigational Drugs·Garam LeeMarwan N Sabbagh
Oct 7, 2020·Expert Opinion on Pharmacotherapy·Francesco PanzaBruno P Imbimbo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
Anne-Lenora HenriksenJohn T Tran
Expert Opinion on Pharmacotherapy
Francesco PanzaGiancarlo Logroscino
© 2022 Meta ULC. All rights reserved